

Press Release

ProStrakan Group plc

ProStrakan Announces Filing of MAA for Sancuso®

Galashiels, Scotland, 16 July 2007 ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, today announces that it has submitted a marketing authorisation application (MAA) across Europe for Sancuso®, a transdermal granisetron patch for the prevention of chemotherapy-induced nausea and vomiting. The news follows the announcement of Sancuso's NDA filing in the US in June.

Many patients undergoing chemotherapy experience acute nausea and vomiting either immediately after chemotherapy or for up to five days. ProStrakan's transdermal patch delivers granisetron, an established 5-HT₃ receptor antagonist, steadily into the bloodstream, which prevents this side-effect without the need for injection or having to swallow pills. ProStrakan announced positive results from the pivotal Phase III programme on Sancuso® in patients undergoing multi-day chemotherapy in December 2006.

Subject to successful completion of the EU approval process, the Company anticipates the EU launch of Sancuso® in H1 2009. As previously announced, ProStrakan submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration in June 2007 and the Group is currently awaiting confirmation of the acceptability of this filing. The NDA filing is a prelude to ProStrakan establishing a US sales and marketing presence.

Commenting on today's announcement, Dr Wilson Totten, ProStrakan's Chief Executive, said: "The filing of the MAA for Sancuso® is a further achievement in our programme to launch three key products over the next twelve months. We continue to make excellent progress to successfully commercialise our existing product portfolio and are well positioned to take advantage of further growth opportunities."

Ends

For further information, please contact:

ProStrakan +44 (0)1896 664000
Dr Wilson Totten, Chief Executive
Paul Garvey, Chief Financial Officer
Callum Spreng, Corporate Comms Director

Financial Dynamics +44 (0)20 7831 3113
David Yates / Ben Brewerton

Trout Group (for US investor enquiries)
Gitanjali Jain (646) 378-2949

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries.
www.prostrakan.com